Entities / Company
Amgen.
American multinational biopharmaceutical company
- Reports this week
- 6
- Active events
- 6
- Connections
- 509
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Morgan Stanley and Citigroup raised price objectives on Amgen shares, with MarketBeat reporting the consensus rating.Some support1 report
-
Amgen, Vertex, and Incyte shares traded on Nasdaq, and Robert A. Bradway leads Amgen's long-term growth strategy.Some support1 report
-
Analyst reports are driving stock market sentiment for Ballard Power Systems, AstraZeneca, Amgen, and Amazon.Some support1 report
-
AbbVie, MIT, Amgen, and John Doerr are Limited Partners in Yosemite's fund.Some support1 report
-
Jay Bradner is a doctor at Amgen.Some support4 reports
-
PepsiCo, Walmart, and Amgen are confirmed to be listed on the Nasdaq exchange.Some support1 report
Earlier this month
-
Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Well supported9 reports1 development inside
-
Amgen's drug Imdelltra showed positive Phase 3 trial results and is now being combined with Imfinzi in new trials.Some support1 report
-
A Harvard instructor attended a Life Sciences Summit while Michaela Kerrissey is an associate professor and Stanley Shaw leads Amgen.Some support1 report
-
Amgen and Google stock movements offset each other on October 29, 2026.Some support1 report
-
Peter Griffith serves as the Chief Financial Officer at Amgen.Some support3 reports
-
MSKCC director Rudin presented trial data involving Amgen on October 25, 2026.Some support1 report
-
Amgen and Gilead Sciences are two companies that compete within the biotech industry.Some support1 report
-
Zai Lab presented data at a meeting in Barcelona, involving researcher Pedro Rocha and Amgen.Some support1 report
-
AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.Some support1 report1 development inside
-
Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Well supported11 reports6 developments inside
-
Laurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.Some support1 report
-
Reports on market moves involving Nike, Amgen, and Investopedia, amidst the ongoing Iran conflict.Some support1 report
-
Amgen and Merck are currently competing against each other in the market for investor capital.Some support4 reports
-
Amgen Inc. trades on the NASDAQ stock exchange.Well supported23 reports
-
A guide on retirement income strategies was provided, noting strong dividend coverage cushions for Procter & Gamble and Amgen.Some support1 report
-
A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.Some support4 reports1 development inside
-
Major pharmaceutical companies are competing for investment capital.Some support1 report
-
Amgen and Eli Lilly committed to adopting Veeva's CRM platform, while Jim Cramer discussed Veeva's recovery from AI fears.Some support1 report
-
Amgen announced funding initiatives aimed at promoting vision care.Some support1 report
One to three months ago
-
Several financial firms acquired or boosted their holdings in Amgen shares on October 7, 2026.Some support1 report
-
AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.Some support1 report
-
Companies including ConocoPhillips, Amgen, Procter & Gamble, Coca-Cola, Texas Instruments, and Qualcomm are noted as part of the SCHD portfolio.Well supported4 reports
-
Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Some support1 report
-
Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Some support2 reports
-
AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.Some support13 reports10 developments inside
-
Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.Well supported131 reports40 developments inside
-
Intuit provides financial management services including TurboTax, Mailchimp, and Credit Karma, alongside developing innovative medicines.Well supported10 reports1 development inside
-
Trump's tariff plan caused markets to tank, affecting company Flo.Some support79 reports12 developments inside
-
Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Well supported4 reports12 developments inside
-
The EPA recognized Amgen's green chemistry efforts, involving VP Margaret Faul, who previously worked at Eli Lilly.Some support1 report
-
Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.Some support1 report
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Amgen and Deloitte are cited as examples of companies undergoing industry transformation.Some support1 report
-
Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.Some support1 report
-
Berkshire Hathaway disclosed a large share purchase of Amgen on September 22, 2026.Some support1 report
-
Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.Some support1 report1 development inside
-
Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.Some support1 report
-
Both Amdocs and Amgen are currently subject to analyst reviews.Some support1 report
-
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Some support2 reports7 developments inside
-
Analyst upgrades and downgrades are affecting the stock performance of Amgen and CF Industries.Some support1 report
-
Amgen and Novartis have developed similar drugs aimed at treating heart conditions.Some support6 reports2 developments inside
-
A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.Some support1 report
-
Novartis' drug failure has negatively impacted Amgen's financial outlook.Some support2 reports1 development inside
-
The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.Some support2 reports
-
Amgen discusses biotech and pharma trends with Wells Fargo, where Thomas Dittrich serves as the company's Chief Financial Officer.Some support1 report
-
Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.Some support1 report
-
Barclays raises S&P 500 target, Amgen stock slumps after trial failure, and oil prices rise due to escalating Middle East hostilities.Some support1 report
-
Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.Some support1 report
-
Reports on the top holdings of various healthcare and biotech ETFs, listing major pharmaceutical companies like Eli Lilly, Amgen, and Johnson & Johnson.Some support1 report
-
Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.Some support3 reports1 development inside
-
Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.Some support2 reports
-
Amgen's stock price was impacted by clinical trial disappointments, while Brent crude influenced S&P 500 market movement.Some support1 report
-
Amgen and AstraZeneca announced a collaborative development of a combination therapy.Some support5 reports1 development inside
-
Joint drug trial success boosts Amgen stock.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Amgen
Events traced to Amgen, step by step, newest first- Novartis's pipeline growth may intensify competition for AmgenNovartis's pipeline success intensifies competitive pressure on AmgenPossible
- Eli Lilly's acquisition may intensify competition for AmgenEli Lilly's enhanced RNA therapeutics capabilities could intensify competition for AmgenPossible
- Amgen may benefit from growing CDMO capacity and demandAmgen may benefit from growing CDMO capacity and demandPossible
- Skyrizi's expanded approval may increase competition for Amgen in Crohn's diseaseSkyrizi's expanded approval may increase competition for Amgen in Crohn's diseasePossible
- AbbVie's immunology expansion may increase competitive pressure on AmgenAbbVie's acquisition of Apogee could intensify competition for Amgen in immunologyPossible
- Competitor GLP-1 expansion could pressure Amgen's market shareIncreased competition in GLP-1 market may pressure Amgen's revenue and pricingPossible
See all 10 explainers
- Novo Nordisk's GLP-1 leadership intensifies competition for AmgenNovo Nordisk's GLP-1 dominance increases competitive pressure on AmgenLikely
- Sanofi's expanded Dupixent access increases competition for AmgenSanofi's expanded Dupixent access increases competition for AmgenPossible
- Increased biotech investment in Boston may raise competitive pressure on AmgenIncreased biotech investment in Boston may raise competitive pressure on AmgenPossible
- Pluvicto access barriers may shift competitive dynamics for AmgenPluvicto access barriers may shift competitive dynamics for AmgenPossible
Around Amgen this week
News at the entities that move Amgen most-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves Amgen
-
Norges Bank TransactionalNorges Bank, BNP Paribas, Morgan Stanley, and Benchmark made various investment moves regarding Datadog shares on June 15, 2026.Moves Amgen
-
Securities and Exchange Commission StructuralStar Holdings sold a land parcel in Coney Island and filed its quarterly report with the SEC.Moves Amgen
-
Quantinuum StructuralIntel brought jobs to Rio Rancho, Quantinuum established operations in Albuquerque, and quantum computing is set to transform New Mexico's economy.Moves Amgen
-
Colorado StructuralFlooding from the Animas River damaged the Durango & Silverton Narrow Gauge Railroad in Colorado.Moves Amgen
-
Medicare StructuralMedicare drug pricing program caused sales pressure on Publix.Moves Amgen
Connections
The 40 strongest of 509, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Jay Bradner Structural
Jay Bradner holds an executive vice president role in R&D at Amgen.
-
Novartis Operational
Amgen and Novartis are direct competitors in the biopharmaceutical market, where clinical trial outcomes and market events of one significantly impact the other's stock performance and risk profile.
-
Thomas Dittrich Structural
Thomas Dittrich serves as the Chief Financial Officer of Amgen.
-
Horizon Therapeutics Structural
Amgen acquired Horizon Therapeutics, making it a subsidiary and integrating its rare disease portfolio.
-
Robert A. Bradway Structural
Robert A. Bradway holds the formal position of CEO and Chairman of Amgen.
-
Pfizer Operational
Pfizer and Amgen are major pharmaceutical competitors actively vying for market share in specialized therapeutic areas, including GLP-1 drugs and biosimilars.
-
Cencora Structural
Amgen relies on Cencora as a critical distributor and wholesaler for its pharmaceutical products and revenue concentration.
-
Genome Valley Structural
Amgen is establishing a dedicated Science and Innovation Center within the Genome Valley ecosystem.
Show all 40 connections
-
Eli Lilly and Company Operational
Both companies are direct competitors in the advanced drug market, specializing in GLP-1 agonists and Lp(a) reduction therapies.
-
Peter Griffith Structural
Peter Griffith held the formal executive role of Chief Financial Officer (CFO) at Amgen.
-
Onyx Pharmaceuticals Structural
Amgen acquired Onyx Pharmaceuticals for $10 billion, establishing a parent-subsidiary relationship.
-
Novo Nordisk Operational
Amgen and Novo Nordisk are direct competitors in the GLP-1 and obesity drug markets.
-
Nasdaq Structural
Amgen is formally listed and traded on the Nasdaq stock exchange.
-
Jyothis George Structural
Jyothis George held a Global Medical Vice President role at Amgen and drove strategic decision making for the company.
-
SEC Structural
Amgen operates under formal financial reporting and disclosure requirements mandated by the SEC.
-
Norges Bank Transactional
Norges Bank purchased a new stake in Amgen stock.
-
Securities and Exchange Commission Structural
Amgen is subject to mandatory regulatory filings and oversight by the Securities and Exchange Commission.
-
AbbVie Operational
AbbVie and Amgen are direct competitors and peers within the biopharmaceutical sector, particularly in the psoriatic arthritis market.
-
Morgan Stanley Operational
Morgan Stanley actively provides market research and price target recommendations on Amgen, influencing its market valuation.
-
FDA Structural
The FDA formally regulates Amgen's drug development, approval, and market use, dictating its operational scope.
-
Cardinal Health Structural
Amgen relies on Cardinal Health as a critical distributor for its products and revenue concentration.
-
Quantinuum Structural
Amgen utilizes Quantinuum's quantum computing platform as a critical component for its advanced operations.
-
Invesco Structural
Invesco holds a large, persistent investment position in Amgen stock.
-
Margaret Faul Structural
Margaret Faul is employed as a Vice President at Amgen.
-
Royalty Pharma Structural
Royalty Pharma holds royalty rights to Amgen's drugs, establishing a persistent financial dependency on Amgen's sales.
-
Merck Operational
Amgen and Merck are active competitors in the biosimilar market and compete for investor capital and market growth.
-
Colorado Structural
Colorado state regulators impose price caps and affordability board actions on Amgen's drug products.
-
Pirow Bekker Transactional
Amgen acquired ChemoCentryx, the company that employed Pirow Bekker.
-
AstraZeneca Operational
Amgen and AstraZeneca maintain a relationship characterized by active market competition alongside formal collaborative drug development and joint trials.
-
Veeva Systems Structural
Veeva provides clinical trial and CRM platforms that Amgen utilizes for operational efficiencies and collaboration.
-
Johnson & Johnson Operational
Johnson & Johnson and Amgen actively compete in the biopharma sector, particularly in immunology and bispecific antibodies, through product launches and market positioning.
-
Sanofi Operational
Sanofi and Amgen are direct competitors operating in the biopharma sector, vying for market leadership in dyslipidemia treatment.
-
Medicare Structural
Medicare regulates Amgen's pricing and sets benchmarks for drug costs under the Inflation Reduction Act.
-
Donald Trump Operational
Trump leverages his political influence and policy proposals, including tariffs and drug pricing agreements, to impact Amgen's market operations and business outlook.
-
Astellas Pharma Operational
Amgen and Astellas Pharma engage in strategic collaborations.
-
David Reese Structural
David Reese holds a senior executive role (EVP & CTO) at Amgen, demonstrating deep functional integration.
-
Mizuho Securities Operational
Mizuho Securities influences Amgen's stock valuation by issuing positive price target recommendations.
-
MCK Structural
MCK functions as a key distributor and wholesaler for Amgen, upon which Amgen relies for revenue concentration.
-
Fred Hassan Structural
Fred Hassan held formal board roles at Amgen.
-
Mizuho Transactional
Mizuho published a report that raised its price objective for Amgen, representing a specific market assessment of Amgen's value.
History
Events by the month they beganNovember 2026
5 events- Morgan Stanley and Citigroup raised price objectives on Amgen shares, with MarketBeat reporting the consensus rating.
- Amgen, Vertex, and Incyte shares traded on Nasdaq, and Robert A. Bradway leads Amgen's long-term growth strategy.
- Analyst reports are driving stock market sentiment for Ballard Power Systems, AstraZeneca, Amgen, and Amazon.
- AbbVie, MIT, Amgen, and John Doerr are Limited Partners in Yosemite's fund.
- PepsiCo, Walmart, and Amgen are confirmed to be listed on the Nasdaq exchange.
October 2026
15 events- Amgen's drug Imdelltra showed positive Phase 3 trial results and is now being combined with Imfinzi in new trials.
- A Harvard instructor attended a Life Sciences Summit while Michaela Kerrissey is an associate professor and Stanley Shaw leads Amgen.
- Amgen and Google stock movements offset each other on October 29, 2026.
- MSKCC director Rudin presented trial data involving Amgen on October 25, 2026.
- Amgen and Gilead Sciences are two companies that compete within the biotech industry.
- Zai Lab presented data at a meeting in Barcelona, involving researcher Pedro Rocha and Amgen.
- Laurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.
- Reports on market moves involving Nike, Amgen, and Investopedia, amidst the ongoing Iran conflict.
- A guide on retirement income strategies was provided, noting strong dividend coverage cushions for Procter & Gamble and Amgen.
- Major pharmaceutical companies are competing for investment capital.
- Amgen and Eli Lilly committed to adopting Veeva's CRM platform, while Jim Cramer discussed Veeva's recovery from AI fears.
- Amgen announced funding initiatives aimed at promoting vision care.
- Several financial firms acquired or boosted their holdings in Amgen shares on October 7, 2026.
- AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.
- Companies including ConocoPhillips, Amgen, Procter & Gamble, Coca-Cola, Texas Instruments, and Qualcomm are noted as part of the SCHD portfolio.
September 2026
23 events- Amgen and Merck are currently competing against each other in the market for investor capital.
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.
- The EPA recognized Amgen's green chemistry efforts, involving VP Margaret Faul, who previously worked at Eli Lilly.
- Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.
- Amgen and Deloitte are cited as examples of companies undergoing industry transformation.
- Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.
- Berkshire Hathaway disclosed a large share purchase of Amgen on September 22, 2026.
- Several biotech companies reported clinical trial setbacks, including Argenx and Immunovant, while Sling Therapeutics' drug was compared to offerings from Viridian and Amgen.
- Both Amdocs and Amgen are currently subject to analyst reviews.
- Analyst upgrades and downgrades are affecting the stock performance of Amgen and CF Industries.
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
- A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.
- Novartis' drug failure has negatively impacted Amgen's financial outlook.
- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
- Amgen discusses biotech and pharma trends with Wells Fargo, where Thomas Dittrich serves as the company's Chief Financial Officer.
- Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.
- Barclays raises S&P 500 target, Amgen stock slumps after trial failure, and oil prices rise due to escalating Middle East hostilities.
- Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
- Reports on the top holdings of various healthcare and biotech ETFs, listing major pharmaceutical companies like Eli Lilly, Amgen, and Johnson & Johnson.
- Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.
- Amgen's stock price was impacted by clinical trial disappointments, while Brent crude influenced S&P 500 market movement.
- Amgen and AstraZeneca announced a collaborative development of a combination therapy.
- Joint drug trial success boosts Amgen stock.
Show 2 earlier months
August 2026
2 eventsJune 2026
15 events- Jay Bradner is a doctor at Amgen.
- Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.
- Peter Griffith serves as the Chief Financial Officer at Amgen.
- AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Amgen Inc. trades on the NASDAQ stock exchange.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.
- Intuit provides financial management services including TurboTax, Mailchimp, and Credit Karma, alongside developing innovative medicines.
- Trump's tariff plan caused markets to tank, affecting company Flo.
- Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).